SAB BIO to Participate in Upcoming Investor Conferences

Rhea-AI Summary

SAB Biotherapeutics (Nasdaq: SABS) said members of management will participate in two investor conferences in Miami Beach in March 2026: the Leerink Partners Global Healthcare Conference on March 9 at 3:00 p.m. ET and the Barclays 28th Annual Global Healthcare Conference on March 11 at 8:30 a.m. ET.

Both appearances are in a fireside chat format. According to the company, live webcasts and archived recordings will be available in the Investors & Media section of the company website at www.sab.bio.

News Market Reaction – SABS

-0.73%

-0.73% Session close to close

In the Mar 2 session, SABS declined 0.73%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

MIAMI, March 02, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company developing a fully human anti-thymocyte immunoglobulin (hATG) for type 1 diabetes (T1D) and other autoimmune diseases, today announced that members of its management team will participate in the following investor conferences in March:

Leerink Partners Global Healthcare Conference
Date: March 9, 2026
Time: 3:00 p.m. ET
Format: Fireside Chat
Location: Miami Beach, FL

Barclays 28^th Annual Global Healthcare Conference
Date: March 11, 2026
Time: 8:30 a.m. ET
Format: Fireside Chat
Location: Miami Beach, FL

To access a live webcast of these events, as well as an archived recording, please visit the Investors & Media section of the Company’s website at www.sab.bio.

About SAB BIO
SAB BIO is a clinical-stage biopharmaceutical company focused on developing multi-specific, high-potency, human immunoglobulin G (hIgG) to treat and prevent immune and autoimmune disorders. Using advanced genetic engineering and antibody science, SAB BIO developed a proprietary technology which holds the potential to generate additional novel therapeutic candidates utilizing the human immune response, without the need for human donors or convalescent plasma. SAB BIO has optimized genetic engineering in the development of transchromosomic cattle, or Tc-Bovine™, to produce hIgG. SAB BIO’s drug development production system is able to generate a diverse repertoire of specifically targeted, high-potency, hIgGs that can address a wide range of serious unmet needs in human diseases. The Company’s lead candidate, SAB-142, targets autoimmune T1D with a disease-modifying therapeutic approach that aims to change the T1D treatment paradigm by delaying onset and potentially preventing disease progression of Stage 3 T1D patients. SAB-142 is currently being evaluated in newly diagnosed Stage 3 autoimmune T1D patients in a registrational Phase 2b clinical trial called SAFEGUARD. For more information, visit www.sab.bio.

CONTACTS
Investors:
Cristi Barnett
ir@sab.bio

Media:
Sheila Carlson
media@sab.bio

FAQ

When will SAB Biotherapeutics (SABS) present at the Leerink Partners Global Healthcare Conference?

SAB Biotherapeutics will present on March 9, 2026 at 3:00 p.m. ET in a fireside chat. According to the company, management will appear in Miami Beach and a live webcast plus archived recording will be available on the company website.

What time is the SAB Biotherapeutics (SABS) fireside chat at the Barclays Healthcare Conference?

The SAB Biotherapeutics fireside chat is scheduled for March 11, 2026 at 8:30 a.m. ET. According to the company, the session will take place in Miami Beach and will be webcast live with an archived recording on the investor site.

How can investors watch SAB Biotherapeutics (SABS) conference presentations in March 2026?

Investors can watch via live webcast and later view archived recordings on the company website. According to the company, webcasts for both March 9 and March 11 events will be posted in the Investors & Media section at www.sab.bio.

Which format will SAB Biotherapeutics (SABS) use for its March 2026 investor conference appearances?

Both March appearances will be conducted as fireside chats according to the company. These conversational formats typically feature management discussion and Q&A and will be webcast and archived on the company’s investor website for later viewing.

Where are the March 2026 conferences with SAB Biotherapeutics (SABS) being held?

Both investor conferences are located in Miami Beach, Florida, in March 2026. According to the company, management will attend the Leerink event on March 9 and the Barclays event on March 11, with webcasts available online.